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doi:10.101Rituximab Administration within 6 Months
of T Cell-Depleted Allogeneic SCT is Associated
with Prolonged Life-Threatening Cytopenias
Zachariah McIver, Nicole Stephens, Andrew Grim, A. John BarrettThe monoclonal anti-CD20 antibody Rituximab (RTX) is increasingly used in allogeneic stem cell transplanta-
tion (SCT) to treat lymphoproliferative disorders and chronic graft-versus-host disease (GVHD). RTX
administration can be complicated by delayed and prolonged neutropenia, but the mechanism is unclear. We
report the occurrence of profound cytopenias following RTX given in the conditioning regimen or early after
T cell-deplete SCT to treat B cell lymphoproliferative disorders or chronic GVHD (cGVHD). Between 2006
and 2009, 102 patients (median age: 43 years, range: 13-68 years), received a myeloablative matched-sibling T
cell-deplete SCT for lymphoid or myeloid hematologic disorders. Neutropenia occurring within 4 weeks of
treatment developed in 16 of 17 patients given RTX within the first 190 days after SCT. Fourteen patients de-
veloped severe neutropenia (count\0.5K/mL) lasting up to 10months and 12 required hospitalization to treat
severe neutropenic infections. Six of the 14 patients died of infection complicatingGVHD treatment. Recovery
of lymphocytes and immunoglobulins was also delayed, with a significantly lower absolute lymphocyte counts
(ALC) at 9 months and 12 months post-SCT compared to patients with cGVHD not treated with early RTX
(P\.02). In contrast, patients receiving RTX 1 year after SCTexperienced only moderate neutropenia 3 to 5
months after treatment lasting 10 to 20 dayswhilemaintaining absolute neutrophil count (ANC).1.0 109/L.
Although RTX rapidly controlled cGVHD, we conclude that its administration early after T cell-deplete SCT is
associated with prolonged profound and life-threatening cytopenias, and should be avoided.
Biol Blood Marrow Transplant 16: 1549-1556 (2010) Published by Elsevier Inc. on behalf of American Society for Blood and
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mortalityINTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(SCT) offers the possibility of a curative treatment for
malignant and nonmalignant hematologic diseases.
However, SCT is frequently complicated by graft-
versus-host disease (GVHD), which remains a major
cause of transplant-related morbidity and mortality
(TRM). The anti-CD20 chimeric monoclonal antibody
Rituximab (RTX) given prior to, or during, conditioningStem Cell Allotransplantation Section, Hematology
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6/j.bbmt.2010.05.004for T cell-replete SCT has been reported to decrease
acute GVHD, and chronic GVHD (aGVHD, cGVHD),
and may decrease TRM [1–3]. Because of these
promising results, RTX has been increasingly used to
treat cGVHD [4].
RTX induces response rates in about two-thirds of
patients with cGVHD. Response varies by organ, with
an estimated response rate of 60% for cGVHD of the
skin compared to approximately 30% for cGVHD of
the gastrointestinal (GI) tract, liver, or lung [5]. Apart
from acute infusion reactions, RTX is well tolerated.
However, late adverse effects are being identified
with increased frequency. Late-onset neutropenia is
estimated to occur in up to 35% of patients treated
for B cell malignancies in the non-SCT setting [6].
Thrombocytopenia (platelets\75 K/mL) and anemia
(hemoglobin \10 g/dL) have also been reported,
with an incidence of approximately 12% and 6%,
respectively [7].
Since 2006, we have used RTX in the early trans-
plant period after myeloablative SCT, either as part
of the conditioning regimen for B cell malignancies,
or to treat emerging cGVHD. Although patients1549
1550 Biol Blood Marrow Transplant 16:1549-1556, 2010Z. McIver et al.with cGVHD responded well to RTX, all patients who
received RTX within 6 months after SCT had a high
risk of developing severe cytopenias. Here, we describe
the clinical outcome of RTX-treated patients and dis-
cuss the possible etiology of RTX-induced cytopenias
in this patient population.MATERIALS AND METHODS
Patients and Controls
Between February 2004 and April 2009, 102 con-
secutive patients underwent a T cell-depleted SCT
from an HLA-identical sibling in 3 successive National
Heart, Lung and Blood Institute (NHLBI) institu-
tional review board-approved protocols (04-H-0112,
06-H-0248, and 07-H-0136). Patients and donors
provided written informed consent before enrolling
in the transplantation protocol.
All patients received a conditioning regimen of
fludarabine 125 mg/m2 over 5 days, fractionated
total-body irradiation (TBI) 12 Gy (4.0 Gy if over
55y) in 8 fractions over 4 days, followed by cyclophos-
phamide 120 mg/kg over 2 days. All transplants were
depleted of T lymphocytes with the Isolex system
(protocol 04-H-0112), or with the Miltenyi CliniMacs
system (Miltenyi Biotec Inc., Auburn, CA) (protocols
06-H-0248 and 07-H-0136) as previously described
[8,9]. In protocols 04-H-0112, 06-H-0248 patients
received an infusion of donor lymphocytes between
days 60 to 90 after SCT. In protocol 07-H-0136
patients received 5  106 selectively depleted CD31
cells/kg on day 0, as previously described [10].
Only patients surviving 6 months or longer after
SCT were included in the analysis to allow sufficient
time for the development of cGVHD, and to exclude
patients that experienced early deaths because of unre-
lated causes. Of the 95 patients surviving 6 months or
longer after SCT, 17 received RTX within 6 months of
SCT. Twenty-eight patients developed cGVHD but
did not receive RTX early after SCT (4 received
RTX 1-7 years after SCT), 18 of whom received an
SCT prior to the use of RTX for treatment of cGVHD
at our institution and were therefore considered the
historic controls for this analysis. Fifty patients did
not develop cGVHD and did not receive RTX at any
time after SCT. Chronic GVHD was diagnosed and
graded consistent with NIH consensus criteria [11].GVHD Prophylaxis
All patients received low-dose (LD) cyclosporine
(CsA) (target plasma level, 100-200 mg/mL), starting
on day 24 and continuing according to protocol to
day 121 or day 90 after SCT. CsA was reinitiated
and continued for approximately 3 months after donor
lymphocyte infusions (DLIs) given by protocol or totreat incipient rejection as documented by falling
counts and falling donor T cell chimerism. CsA was
continued or reinitiated if cGVHD developed, and
patients were treated off protocol for cGVHD refrac-
tory to CsA and prednisone.Infection Prophylaxis and Treatment
Standard prophylaxis against infection included
fluconazole and bactrim given for at least 6 months after
transplantation, and twice weekly surveillance for
cytomegalovirus (CMV) DNA by polymerase chain
reaction (PCR). Treatment of infections was in accor-
dance with the Guidelines for Management in Alloge-
neic Hematopoietic Stem Cells Transplant Recipients
published by the Center for Disease Control (CDC)
(http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4
910a1.htm). Granulocyte colony stimulating factor
(G-CSF) was administered in all cases to maintain
and absolute neutrophil count (ANC) .500/mL.RTX Administration and Response Criteria
RTX given in the first 6 months after SCT was
administered by intravenous infusions of RTX (375
mg/m2 per infusion) at 2 to 4 weekly intervals posttrans-
plant to treat cGVHD (15 patients), Epstein-Barr virus
(EBV) lymphoproliferative disease (1 patient), and
autoimmune hemolytic anemia (1 patient). Three pa-
tients with B cell malignancies that received RTX for
treatment of cGVHD also received RTX immediately
prior to, or as part of, the SCT conditioning regimen.
In addition, 4 patients received RTX 1 to 7 years
post-SCT at the same dose and schedule to treat
cGVHD. Response of cGVHD to RTX was assessed
1 month after the last infusion. Complete response
(CR) was defined as resolution of all manifestations of
cGVHD in involved organs. A partial response (PR)
was defined as an improvement in 1 or more involved
organ without any progression or new organ involve-
ment. Resistance was defined as no response or worsen-
ing cGVHD requiring alternative therapy.Statistical Analysis
Survival was measured to the last contact date or
death. Univariate and multivariate analyses were per-
formed using Cox proportional-hazard regression
model, including all factors associated with a P-value
\.2 by univariate analysis, and all factors statistically
different among the early RTX and other groups
(P \.10). A stepwise backward procedure was then
used with a cutoff significance level of .05 to remove
factors from the model. P-values are 2 sided, with
a type I error rate fixed at .05. Statistical analyses
were performed with SPSS 15.0 and Prism 4 software.
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Life-Threatening CytopeniasRESULTS
cGVHD Response to RTX
Eight of the 15 patients who received RTX for
treatment of cGVHD during the first 6 months after
SCT experienced complete remission of all cGVHD
symptoms shortly after RTX administration, 4 pa-
tients developed a PR but continued to require first-
line cGVHD treatment, and 3 patients required
further second-line treatment (Table 1). All 4 patients
receiving RTX 1 to 7 years after SCT responded, 3
with CR and 1 with PR.
Blood Counts and Immunoglobulin Levels
during the First 12 Months after SCT
Onset of cytopenias occurred a median of 4 weeks
after administration of RTX and led to a significant
difference in blood counts between the 3 groups (early
RTX, cGVHD without early RTX, no cGVHD) dur-
ing the first year after SCT (Figure 1A-C). Patients
treated within 6 months after SCT with RTX experi-
enced lower absolute neutrophil counts at 6 months
and 9 months (P \.01). These patients also experi-
enced lower absolute lymphocyte counts throughout
the first posttransplant year (P \.01 at 6, 9, and 12
months), a lower median platelet count at 6 months af-
ter SCT (P\.01), and lower immunoglobulin levels
for up to 2 years post-SCT. The median level of IgM
was lowest at 9 months after SCT, and occurred 12
months or later for IgG and IgA (Figure 1E). Clinically
significant anemia requiring red blood cell (RBC)
transfusions was infrequently noted. However, no
difference in erythropoeitic activity was noted between
the 3 groups as represented by equivalent absolute
reticulocyte counts during the first year after SCT,
and anemia requiring RBC transfusions occurred
infrequently (Figure 1D).
Timing of RTX Administration and Severity of
Lymphopenia Correlates with Duration of
Neutropenia
The earlier RTX was given after SCT, the longer
was the duration of cytopenias. Patients receiving their
first dose of RTX at least 20 weeks after SCT experi-
enced relatively short episodes of cytopenias with
a mean duration of moderate neutropenia (ANC
\1000 cells/mL) of 1.3 months, and of severe neutrope-
nia (ANC\500 cells/mL, G-CSF dependence) of 0.6
months. In contrast, patients receiving RTX between
10 and 20 weeks after SCT experienced prolonged
neutropenia (mean duration 3.3 months of moderate
neutropenia, and 1.7 months of severe neutropenia).
Patients treated with RTX within 10 weeks of SCT
experienced the longest cytopenias (mean duration of
13.7 months of moderate neutropenia, and 5 months
of severe neutropenia) (Figure 2). In total, 16 of the
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Figure 1. (A-E) Median absolute peripheral counts during the first year after SCT, and median absolute IgG immunoglobulin levels during the first 2
years after SCT. – – – No cGVHD; ––– cGVHD without early RTX; –  – Early RTX.
1552 Biol Blood Marrow Transplant 16:1549-1556, 2010Z. McIver et al.17 patients developed severe neutropenia, 5 of which
experienced only a minimal responsive to prolonged
G-CSF administration. All 4 patients receiving RTX
1 to 7 years after SCT experienced only moderate neu-
tropenia 3 to 5 months after treatment lasting 10 to 20
days while maintaining ANC .1.0  109/L.Figure 2. Timing of RTX administration and duration of neutropenia. Mean du
dose of RTX within various time periods in relation to SCT. Duration of cytop
tration and SCT; patients that received RTX within 10 weeks of SCTexperienRTX administration was associated with a profound
nadir in absolute lymphocyte counts (ALC) occurring
within 4 weeks after the administration of the last
dose. Patients developing an ALC nadir less than the
median of 140 lymphocytes/mL experienced the longest
duration of neutropenia (ANC \1000/mL, median 7ration of cytopenias experienced by patients when treated with their first
enias inversely correlated with the time interval between RTX adminis-
cing the longest duration of neutropenia and lymphopenia.
Table 2. Patients with cGVHDWho Received RTX within 30 Weeks of SCT
Disease
Indication
for RTX
Week of
First Dose
of RTX
Week of
Chronic
GVHD Onset
Organs Involved
with Chronic
GVHD
cGVHD Severity
(NIH Consensus
Criteria)
Treatment of
Chronic GVHD
Prior to RTX
No. of Doses
within 30 weeks
of SCT
Other Second-
Line Treatments
after RTX
MCL NHL, GVHD 28 13 Skin, Joints Mild Pred, CsA 3
MCL NHL, GVHD 25 14 Skin, Joints, GI Moderate Pred, CsA, MMF 7 Daclizumab and
Infliximab, PhotoPh
CLL CLL , GVHD 0 19 Skin, Liver, GI Moderate Pred, CsA, Tacro, MMF 5
ALL Ph+ GVHD 10 10 Skin, Liver, GI Moderate Pred, CsA 2
AML GVHD 12 12 Skin Mild Pred, CsA 3
ALL Ph+ GVHD 13 12 Skin, GI Moderate Pred, CsA, MMF 2 Daclizumab
and Infliximab
AML GVHD 15 13 Skin, Joints Moderate Pred, CsA, MMF 3
MDS GVHD 15 13 Skin, Joints Moderate Pred, CsA 2
AML EBV LPD 16 * * * * 3
AML GVHD 16 14 Skin, Joints, Lung Moderate Pred, CsA, MMF 4 Imatinib
MDS/AML GVHD 19 16 Skin, Liver, GI Moderate Pred, CsA, Tacro, MMF 3
AML GVHD 20 19 Skin, Lung Moderate Pred, CsA, MMF 3
ALL Ph+ GVHD 22 16 Skin, Joints Moderate Pred, CsA, MMF 2
ALL Ph2 GVHD 22 16 Skin, Joints Moderate Pred, CsA, MMF 2 Imatinib
APL GVHD 23 18 Skin, Joints, Liver Moderate Pred, CsA, Tacro, MMF 3
APL GVHD 23 14 Skin, Joints, Liver Moderate Pred, CsA, Tracro, MMF 4 Daclizumab
and Infliximab
CML AIHA 27 * * * * 2
RTX indicates rituximab; SCT, stem cell transplantation; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; APL, acute promyelo-
cytic leukemia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin leukemia; MDS, myelodysplastic syndrome;
Ph+, Philadelphia chromosome; EBV, Epstein-Barr virus; AIHA, autoimmune hemolytic anemia; PhotoPh, Photopheresis; CsA, cyclosporine; Tacro,
tacrolimus; Pred, prednisone; GVHD, graft-versus-host disease.
*Received RTX for PTLD and AIHA.
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Life-Threatening Cytopeniasmonths versus 1.5 months, P\.01). Death because of
infection only occurred in this group.Outcomes
All patients received anti-Candida prophylaxis with
fluconazole initiated at time of SCT, and all patients
were switched to voriconazole for anti-Aspergillus
prophylaxis at the time of cGVHD diagnosis with
introduction of steroid therapy. Fourteen of the 17
patients treated with RTX within 6 months of SCT de-
veloped recurrent bacterial infections, with superficial
cellulitis, bacterial pneumonia, and septicemia occur-
ring in the majority of cases (Table 1). Additionally, 6
patients developed significant fungal infections and
5 died with invasive fungal pneumonia (2 Apergillus,
3 Zygomyces). Four patient developed evidence of
autoimmune disorders; 2 with T cell large granular
lymphoproliferative disease (T-LGL), with .30%
CD81CD571 cytotoxic T cells by flow cytometry of
peripheral blood, 1 patient with natural killer (NK)-
LGL (.90% NK dominance of lymphocytes in bone
marrow specimen), and 1 patient with immune throm-
bocytopenic purpura diagnosed clinically and by in-
creased megakaryocytes in the bone marrow biopsy.
Three patients developed aGVHD overlap syndrome
of the gastrointestinal tract, which occurred up to 2.5
years after SCT and was documented by biopsy.
Patients with cGVHD treated with RTX early after
SCT had higher TRM (64% versus 18%,P5 .03) when
compared to all other patients with cGVHD. To
exclude selection bias and the possibility that RTX
was used only to treat the most recalcitrant forms ofcGVHD, we compared results with historic cGVHD
controls not treated with RTX at our institution
(Tables 2, 3, and 4). Again, patients with cGVHD
treated with RTX within 6 months of SCT had
significantly higher TRM compared with the
cGVHD historic controls (64% versus 17%, P 5 .02),
suggesting that the early administration of RTX
increased the risk of TRM independent of cGVHD
status. In univariate and multivariate analysis only
RTX administration was associated with increased
TRM (hazard ratio [HR] 5 5.54, 95% confidence
interval [CI] 1.12-27.2, P5 .03, Figure 3).DISCUSSION
cGVHD is a major cause of SCT-related morbid-
ity and mortality, and steroid dependent or resistant
patients have a worse prognosis. RTX is effective in
the treatment of steroid refractory cGVHD and has
been used increasingly early after SCT to treat
cGVHD in addition to its use in controlling lympho-
proliferative disorders. This report highlights a poten-
tial risk of RTX administration within 6 months of T
cell-depleted SCT.
Although cytopenias are known to occur following
RTX administration, severe RTX-induced cytopenias
have not been described in the context of allogeneic
SCT [6,12]. Previous reports describe only limited
cytopenias when RTX is administered early after T
cell-replete SCT [13,14]. A possible explanation for
the worse outcomes in our patients receiving RTX is
that the risk of cytopenias is related to the T cell
Table 4. Univariate Analysis of Risk Factors for TRM in
Patients with cGVHD
Covariable
cGVHD Not
Receiving
Early RTX
Patients with
cGVHD Treated
with RTX <6
Months of SCT
Univariate
Analysis
P-Value
RTX administration 0/18 patients 15/15 patients .02
Age Median 34
(range: 19-48)
Median 41
(range: 30-58)
.09
Reason for SCT
AML 12 5 .73
ALL 1 4
CML 2 0
NHL 1 3
MDS 2 2
Disease risk
Low 7 1 .69
Intermediate 2 9
High 9 12
Severity of cGVHD
prior to RTX
administration
Mild 6 3 .18
Moderate 12 11
Severe 0 0
Number of organs
involved
1 10 2 .80
2 4 7
3+ 4 5
DLI given 11 3 .10
RTX indicates Rituximab; cGVHD, chronic graft-versus-host disease; SCT,
stem cell transplantation; AML, acute myelogenous leukemia; ALL, acute
lymphoblastic leukemia; CML, chronic myelogenous leukemia; NHL,
non-Hodgkin leukemia; MDS, myelodysplastic syndrome; DLI, donor lym-
phocyte infusion.
Table 3. Historical Controls, Patients with cGVHDWho Did Not Received RTX Early after SCT
Disease
Week of
cGVHD Onset
Organs Involved
with cGVHD
cGVHD Severity
(NIH Consensus Criteria) Treatment of cGVHD
Other Second-Line
Treatments
AML 16 Skin, Joints moderate Pred, CsA, MMF
AML 31 Skin, Liver, Eyes moderate Pred, CsA, MMF
CLL 23 Skin, Joints mild Pred, CsA
AML 19 Skin, Eyes mild Pred, CsA
ALL 14 Liver moderate Pred, CsA, Tacro
MDS 16 Skin, Liver, Mouth moderate Pred, CsA, Tacro
CML 22 Skin, Joints moderate Pred, CsA, MMF
AML 14 Skin, Lungs moderate Pred, CsA
AML 14 Skin, Joints moderate Pred, CsA
AML 16 Skin, Joints mild Pred, CsA
ALL 13 Skin moderate Pred, CsA
CML 15 Skin, Mouth, Eyes moderate Pred, CsA, MMF
AML 10 Skin, Liver, GI severe Pred, CsA, Tacro Daclizumab and Infliximab
AML 14 Skin, Joints, Lung moderate Pred, CsA, MMF
AML 16 Skin, Joints moderate Pred, CsA, MMF Imatinib
AML 12 Skin, Liver moderate Pred, CsA, Tracro Daclizumab and Infliximab
MDS 15 Skin, Renal moderate Pred, CsA
AML 26 Skin, Joints, Eyes moderate Pred, CsA, MMF
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; APL, acute promyelocytic leukemia; CML, chronic myelogenous leuke-
mia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkins Leukemia; MDS, myelodysplastic syndrome; CsA, cyclosporine; Tacro, tacrolimus; Pred,
prednisone; GVHD, graft-versus-host disease; RTX indicates Rituximab.
1554 Biol Blood Marrow Transplant 16:1549-1556, 2010Z. McIver et al.depletion of the graft, which delivers only a limited
quantity of B cells to the recipient. In our patients
whose allografts were manipulated to remove T
lymphocytes,\1  103 B cells/kg were infused at the
time of transplantation, rendering them profoundly B
cell depleted. Additionally, the reduced inoculum of T
cells in the lymphopenic milieu at time of SCT may
have contributed to the risk of cytopenias by
predisposing our patients to clonal expansions of small
numbers of residual CD81 T cells, which further
enhanced the immune imbalance induced by RTX
[15,16].
The mechanism of increased TRM with early
RTX administration after T cell-deplete SCT in our
patient population appears multifactorial involving
impaired B-lymphocyte, neutrophil, and T cell
function. Although the half-life of RTX ranges from
2 to 3 weeks, detectable levels may persist 3 to 6
months after administration [17,18]. Previous studies
have demonstrated that RTX administration within 1
year prior to SCT significantly impaired B cell
reconstitution and resulted in a significant B cell
deficiency lasting up to 2 years after T cell-replete
SCT [19]. Similar to our experience, the duration of
B cell deficiency was also inversely correlated with
the time interval between RTX administration and
SCT, indicating a profound B cell depleting effect of
RTX when given in close proximity to SCT. Com-
pared to other patients, including those with cGVHD,
we found that early RTX recipients had reduced levels
of immunoglobulins and an increased risk of infection.
It was notable that early RTX recipients had lower me-
dian neutrophil counts in the first 9 months after SCT
compared with other patients (including those devel-
oping cGVHD who did not receive early RTX).Clearly, the prolonged neutropenia contributed to
the infectious complications encountered after early
RTX administration despite the aggressive use of
G-CSF, which provided only temporary improvement
of the neutrophil count. The profound lymphopenia
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Figure 3. Administration of RTX to treat cGVHD within 6 months of
SCTwas associated with higher TRM.
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Life-Threatening Cytopeniasaccompanying the neutropenia in our patients was
striking, and was associated with more severe cytope-
nias and worse outcome.
The neutropenia and lymphopenia following RTX
administration is not easily explained. The cytopenias
we observed appear distinct from the effects of
cGVHD because neutrophil, platelet, and lymphocyte
counts were significantly lower than in patients devel-
oping cGVHD who did not receive RTX early after
SCT. In mice, short-term B cell depletion reduces ex-
pansion, activation, and effector cell differentiation of
CD41T cells, whereas CD81 activation is not affected
[20]. A decreased conversion of CD41T cells from the
naı¨ve to a central memory phenotype is also observed,
suggesting that a significant functional and matura-
tional deficiency exists in the CD41 compartment in
the absence of B cell and antigen-specific CD41 T
cell interactions. Similarly in humans, lower CD41
and CD41Foxp31 regulatory T cells are noted in
patients with diseases of defective B cell differentia-
tion, and are associated with an inversion of the
CD41/CD81 ratio and a higher incidence of autoim-
mune disorders [21]. Consequently, the immune
dysregulation occurring after B cell depletion suggests
an immune-mediated mechanism in the pathogenesis
of RTX-associated cytopenias. A recent report demon-
strates that patients who develop RTX-associated late
onset neutropenia have inverted CD41/CD81 ratios
and more pronounced T cell expansions. Proliferation
of T-large granular lymphocytes with increased ex-
pression and secretion of Fas and Fas ligand was also
noted, and bone marrow evaluation demonstrated
dyshematopoiesis with extensive hypoplasia of the
granulocytic series, consistent with findings seen in
immune-mediated T-LGL [22]. The occurrence of
LGL and ITP in 4 patients treated with RTX supports
the possibility that RTX induced clonal expansion of
autoreactive CD81 T cells, which suppressed neutro-
phil production. We are now searching for expanded
LGL CD81 T cell clones in all neutropenic RTX
recipients.In conclusion, RTX is a powerful immune modu-
latory agent that is effective in the treatment of
cGVHD. However, prolonged and life-threatening
cytopenias can occur when RTX is administered
within 6 months of T cell-depleted SCT. Although
the mechanism remains unclear, the increased inci-
dence of auto- and alloimmune diseases after RTX
administration suggests immune dysregulation. We
recommend avoiding RTX administration within 6
months of T cell-deplete SCT to minimize the risk
of life-threatening cytopenias and other immune
mediated adverse events.ACKNOWLEDGMENTS
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